PGAM5 dephosphorylates LCLAT1S410 to trigger cardiolipin oxidation-driven ferroptosis in cadmium-induced metabolic dysfunction-associated steatotic liver disease

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a prevalent, steadily increasing metabolic liver disease characterized by steatosis and liver injury, with disease progression influenced by environmental risk factors. Cadmium (Cd), a ubiquitous environmental metal toxicant, has been epidemiologically associated with MASLD progression. Although mitochondrial dysfunction and oxidative lipid damage contribute to MASLD pathogenesis, whether and how Cd disrupts mitochondrial lipid homeostasis to initiate lipid peroxidation-associated injury remains elusive. In this study, we demonstrate that cardiolipin (CL) oxidation-associated ferroptosis and hepatic lipid accumulation are markedly increased in Cd-exposed mouse livers in vivo and in Cd-treated hepatocytes in vitro, exacerbating liver injury and promoting MASLD progression. Integrated transcriptomic, metabolomic, and lipidomic analyses revealed profound alterations in mitochondrial lipid metabolic pathways, highlighting CL remodeling as a key regulatory layer underlying oxidative lipid damage and ferroptosis-associated liver injury. Mechanistically, phosphoglycerate mutase family member 5 (PGAM5) functions as an upstream regulator. Cd exposure enhances mitochondrial PGAM5–lysocardiolipin acyltransferase 1 (LCLAT1) interaction, triggering PGAM5-dependent LCLAT1 dephosphorylation at serine 410 (S410), thereby reinforcing LCLAT1 mitochondrial translocation, accelerating CL acyl-chain remodeling, and driving CL oxidation-dependent ferroptosis. Pharmacological or genetic PGAM5 inhibition attenuated CL oxidation, ferroptosis, and MASLD-like liver injury in vitro and in vivo. Moreover, PGAM5 and LCLAT1 are upregulated and positively correlated in human MASLD livers. Collectively, these findings define a PGAM5–LCLAT1–CL axis linking cadmium exposure to mitochondria-driven ferroptosis and MASLD progression, and identify PGAM5 as a potential therapeutic target for environmentally associated MASLD.

Authors

Institutions

Publication Details

Journal
Cell Death and Disease
Published
2026-11-19
DOI
https://doi.org/10.1038/s41419-026-09296-7
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

PGAM5 dephosphorylates LCLAT1S410 to trigger cardiolipin oxidation-driven ferroptosis in cadmium-induced metabolic dysfunction-associated steatotic liver disease

Xianliang Wu, Xin-Mou Wu, Zhong‐Ning Lin, Ze‐Bang Du et al.
Cell Death and Disease
Liver Disease Diagnosis and Treatment
article

PGAM5 dephosphorylates LCLAT1S410 to trigger cardiolipin oxidation-driven ferroptosis in cadmium-induced metabolic dysfunction-associated steatotic liver disease

Xianliang Wu, Xin-Mou Wu, Zhong‐Ning Lin, Ze‐Bang Du, Dongbei Guo, Wengang Li, Yu‐Chun Lin, Wen-Hao Han, Yi-Ling Zhang, Xiao-Gang Xia, Wen-Qi Xu, You-Liang Yao
article en

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) represents a prevalent, steadily increasing metabolic liver disease characterized by steatosis and liver injury, with disease progression influenced by environmental risk factors. Cadmium (Cd), a ubiquitous environmental metal toxicant, has been epidemiologically associated with MASLD progression. Although mitochondrial dysfunction and oxidative lipid damage contribute to MASLD pathogenesis, whether and how Cd disrupts mitochondrial lipid homeostasis to initiate lipid peroxidation-associated injury remains elusive. In this study, we demonstrate that cardiolipin (CL) oxidation-associated ferroptosis and hepatic lipid accumulation are markedly increased in Cd-exposed mouse livers in vivo and in Cd-treated hepatocytes in vitro, exacerbating liver injury and promoting MASLD progression. Integrated transcriptomic, metabolomic, and lipidomic analyses revealed profound alterations in mitochondrial lipid metabolic pathways, highlighting CL remodeling as a key regulatory layer underlying oxidative lipid damage and ferroptosis-associated liver injury. Mechanistically, phosphoglycerate mutase family member 5 (PGAM5) functions as an upstream regulator. Cd exposure enhances mitochondrial PGAM5–lysocardiolipin acyltransferase 1 (LCLAT1) interaction, triggering PGAM5-dependent LCLAT1 dephosphorylation at serine 410 (S410), thereby reinforcing LCLAT1 mitochondrial translocation, accelerating CL acyl-chain remodeling, and driving CL oxidation-dependent ferroptosis. Pharmacological or genetic PGAM5 inhibition attenuated CL oxidation, ferroptosis, and MASLD-like liver injury in vitro and in vivo. Moreover, PGAM5 and LCLAT1 are upregulated and positively correlated in human MASLD livers. Collectively, these findings define a PGAM5–LCLAT1–CL axis linking cadmium exposure to mitochondria-driven ferroptosis and MASLD progression, and identify PGAM5 as a potential therapeutic target for environmentally associated MASLD.

Cell Death and Disease
Xiamen University (CN)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon